Physician profile
Mridula Vinjamuri
NPI 1063613503
$7,795.33
in general payments reported to CMS, 2019-2025
58 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $593 · 2021: $690 · 2022: $906 · 2023: $1,573 · 2024: $1,100 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.66 |
| Education | $226.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $525.05 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $455.35 | 2019-2025 | Rybrevant, Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $455.27 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $424.30 | 2019-2025 | |
| Genentech USA, INC. | $419.75 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Novartis Pharmaceuticals Corporation | $410.29 | 2019-2025 | |
| Eisai INC. | $391.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $377.84 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $327.19 | 2020-2025 | Ojjaara, Jemperli |
| Daiichi Sankyo INC. | $269.68 | 2020-2025 | Enhertu, Injectafer |
| Gilead Sciences, INC. | $226.02 | 2019-2025 | Trodelvy |
| Incyte Corporation | $221.47 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Exelixis INC. | $206.88 | 2019-2025 | Cabometyx |
| Sobi, INC | $186.40 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $183.35 | 2019-2023 | Imbruvica |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mridula Vinjamuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.